DealPulse Signal Wk 43: EQT Paid $12.1 Billion for QIAGEN, and Roche Paid $400 Million on a $15.5 Billion ADC Deal
EQT paid $12.1bn for QIAGEN, three drugs sold for $3.1bn in cash, and Roche paid 2.8% upfront on $16.3bn of licences.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days
The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There
Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA
Lilly Signed Up to $1.1 Billion With METiS TechBio for AI-Designed Lipid Nanoparticles While Paying Only Low Double-Digit Millions Upfront
The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod’s Lenire a Coverage Argument
